The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis (Q59689568)
scholarly article by G A Ellard et al published June 1986 in The American Review of Respiratory Disease
Language:
Current Data About The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis
(P31) (Q13442814)

(P304) 1076-80

(P407) (Q1860)

(P433) 6

(P478) 133

(P577) +1986-06-00T00:00:00Z

(P921) (Q12204)
(P887)

(Q417571)
(P887)

(Q422652)
(P887)

(Q423169)

(Q461809)
(P887)

(P1433) (Q26839505)

(P1476) "The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis" (language: en)

(P2093) G A Ellard
(P1545) 1

D R Ellard
(P1545) 2

B W Allen
(P1545) 3

D J Girling
(P1545) 4

A J Nunn
(P1545) 5

S K Teo
(P1545) 6

T H Tan
(P1545) 7

H K Ng
(P1545) 8

S L Chan
(P1545) 9

other details
description scholarly article by G A Ellard et al published June 1986 in The American Review of Respiratory Disease

External Links
(P698) 3717760